SCNX Q2 2026: Revenue up ~510% sequentially; net loss narrows 58% YoY

Scienture Holdings, Inc.

2026-Q2 EPS reported -$0.16 revenue$399,964

Revenue $343,639 in Q2 2026, up ~510% from $56,325 in Q1 2026; H1 revenue $399,964 vs $10,258 in H1 2025.
Net loss narrowed ~58% YoY to ~$2.8M; EPS improved to -$0.07 from -$0.48; operating loss ~$2.7M, down ~48%.
Cash, equivalents and restricted cash ~$11.2M at June 30, 2026, vs ~$6.7M at Dec 31, 2025; gross margin ~97.7%.
Commenced commercial launch of REZENOPY (naloxone nasal spray); second patent granted through 2041.
Arbli expanded payer coverage adding ~12.5M covered lives; third patent granted; targeting profitability in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.